Novo Nordisk stock news
On July 31, 2026, a New Jersey federal judge ruled that a class--action lawsuit against Novo Nordisk can proceed, allowing investors to seek damages for significant stock losses incurred in 2024. The litigation alleges that the company and its executives, including Research Director Martin Holst Lange and former CEO Lars Fruergaard Jørgensen, misled the market regarding clinical trial outcomes for the weight--loss drug CagriSema. This legal development introduces significant liability risks and potential for further share price volatility as the company approaches its Q2 2026 earnings release scheduled for August 5.